# ClinicalTrials.gov record NCT04425746

> PeptideScanner retained ClinicalTrials.gov record NCT04425746 at 2026-07-30T19:57:27.405Z. Its registry update date was 2021-10-01, and PeptideScanner's reviewed identity mapping was afamelanotide.

- Evidence object: `story:clinicaltrials-gov-nct04425746-afamelanotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-10-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04425746-afamelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04425746-afamelanotide-v1.json
- Content SHA-256: `d59b47b3f779e7e74830a98e7a951623734ee159955e58095bb95e721db95190`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04425746 ([`ctg-observation-nct04425746-2021-10-01-ebd90465c1b6`](#source-ctg-observation-nct04425746-2021-10-01-ebd90465c1b6))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04425746 at 2026-07-30T19:57:27.405Z. Its registry update date was 2021-10-01, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct04425746-2021-10-01-ebd90465c1b6`](#source-ctg-observation-nct04425746-2021-10-01-ebd90465c1b6))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04425746 at 2026-07-30T19:57:27.405Z. Its registry update date was 2021-10-01, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct04425746-2021-10-01-ebd90465c1b6`](#source-ctg-observation-nct04425746-2021-10-01-ebd90465c1b6))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04425746-2021-10-01-ebd90465c1b6`](#source-ctg-observation-nct04425746-2021-10-01-ebd90465c1b6))

## Sources

<a id="source-ctg-observation-nct04425746-2021-10-01-ebd90465c1b6"></a>
- **ClinicalTrials.gov record NCT04425746 · retained source version 2021-10-01:ebd90465c1b6b88147508b64284f97d4f803896beb86247c16c65b09f791458a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04425746) (`ctg-observation-nct04425746-2021-10-01-ebd90465c1b6`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04425746." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04425746-afamelanotide-v1.json SHA-256: d59b47b3f779e7e74830a98e7a951623734ee159955e58095bb95e721db95190.